Pediatric Nephrology

, Volume 22, Issue 11, pp 1875–1880 | Cite as

Steroid-resistant nephrotic syndrome: long-term evolution after sequential therapy

  • Antonia PeñaEmail author
  • Juan Bravo
  • Marta Melgosa
  • Carlota Fernandez
  • Carmen Meseguer
  • Laura Espinosa
  • Angel Alonso
  • M. Luz Picazo
  • Mercedes Navarro
Original Article


We present a retrospective study of 30 children of mean age 3.02 ± 1.81 years with steroid-resistant nephrotic syndrome (SRNS) treated with intravenous injection of methylprednisolone plus orally administered prednisone; 24 children also received cyclophosphamide (CP). Sixteen were resistant to steroids from the beginning, and 14 after a mean of 11.26 ± 16.61 months. The initial histological diagnosis was: 18 minimal change disease (MCD), 11 focal segmental glomerulosclerosis (FSGS) and one diffuse mesangial proliferative glomerulonephritis (DMPG). Total remission was achieved in 22 patients (73.3%), partial response in three (10%) and no response in five (16.6%), two of whom were brothers carrying an NPHS2 gene double mutation. There was no difference in response between the MCD and FSGS patients; the only patient with DMPG did not respond. Only initial resistance was a sign of bad prognosis. At follow-up (6.4 ± 3.6 years from last pulse), 21/22 were still in remission, 14/21 were without treatment. Six patients required cyclosporine or mycophenolate mofetil because of steroid dependence. Two non-responders developed end-stage renal failure (ESRF); the remaining patients maintained normal glomerular filtration. The treatment was well tolerated. In conclusion, most of the patients treated with sequential therapy consisting of methylprednisolone (MP) (100%) and CP (80%) showed remission and preserved renal function, but 20% developed steroid dependence.


Steroid-resistant nephritic syndrome Pulses Methylprednisolone Cyclosporine Tacrolimus Mycophenolate mofetil Children 



We would like to give special thanks to Elia Pérez Fernández from the Statistics Department of La Paz Hospital for her help with the statistical analysis of the data.


  1. 1.
    Koskimies O, Vilska J, Rapola J, Hallman N (1982) Long-term outcome of primary nephrotic syndrome. Arch Dis Child 57:544–548PubMedPubMedCentralGoogle Scholar
  2. 2.
    Cattran DC, Rao P (1998) Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 32:72–79PubMedGoogle Scholar
  3. 3.
    Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr (1996) Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol 10:590–593PubMedGoogle Scholar
  4. 4.
    Tejani A (1985) Morphological transition in minimal change nephrotic syndrome. Nephron 39:157–159PubMedGoogle Scholar
  5. 5.
    Tejani A, Nicastri AD, Sen D, Chen CK, Phadke K, Adamson O, Butt KM (1983) Long-term evaluation of children with nephrotic syndrome and focal segmental glomerular sclerosis. Nephron 35:225–231PubMedGoogle Scholar
  6. 6.
    Mendoza SA, Reznik VM, Griswold WR, Krensky AM, Yorgin PD, Tune BM (1990) Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr Nephrol 4:303–307PubMedGoogle Scholar
  7. 7.
    Hodson EM, Habashy D, Craig JC (2006) Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev CD003594Google Scholar
  8. 8.
    International Study of Kidney Disease in Children (1974) Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children. Lancet 2:423–427Google Scholar
  9. 9.
    Rose GM, Cole BR, Robson AM (1981) The treatment of severe glomerulopathies in children using high dose intravenous methylprednisolone pulses. Am J Kidney Dis 1:148–156PubMedGoogle Scholar
  10. 10.
    Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr (1997) Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769–776PubMedGoogle Scholar
  11. 11.
    Alshaya HO, Al-Maghrabi JA, Kari JA (2003) Intravenous pulse cyclophosphamide—is it effective in children with steroid-resistant nephrotic syndrome? Pediatr Nephrol 18:1143–1146PubMedGoogle Scholar
  12. 12.
    Hari P, Bagga A, Jindal N, Srivastava RN (2001) Treatment of focal glomerulosclerosis with pulse steroids and oral cyclophosphamide. Pediatr Nephrol 16:901–905PubMedGoogle Scholar
  13. 13.
    Yorgin PD, Krasher J, Al Uzri AY (2001) Pulse methylprednisolone treatment of idiopathic steroid-resistant nephrotic syndrome. Pediatr Nephrol 16:245–250PubMedGoogle Scholar
  14. 14.
    Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA (1995) Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 43:84–88PubMedGoogle Scholar
  15. 15.
    Mori K, Honda M, Ikeda M (2004) Efficacy of methylprednisolone pulse therapy in steroid-resistant nephrotic syndrome. Pediatr Nephrol 19:1232–1236PubMedGoogle Scholar
  16. 16.
    Kirpekar R, Yorgin PD, Tune BM, Kim MK, Sibley RK (2002) Clinicopathologic correlates predict the outcome in children with steroid-resistant idiopathic nephrotic syndrome treated with pulse methylprednisolone therapy. Am J Kidney Dis 39:1143–1152PubMedGoogle Scholar
  17. 17.
    Bajpai A, Bagga A, Hari P, Dinda A, Srivastava RN (2003) Intravenous cyclophosphamide in steroid-resistant nephrotic syndrome. Pediatr Nephrol 18:351–356PubMedGoogle Scholar
  18. 18.
    Schonwald S (1999) Methylprednisolone anaphylaxis. Am J Emerg Med 17:583–585PubMedGoogle Scholar
  19. 19.
    Saito R, Moroi S, Okuno H, Ogawa O (2004) Anaphylaxis following administration of intravenous methylprednisolone sodium succinate in a renal transplant recipient. Int J Urol 11:171–174PubMedGoogle Scholar
  20. 20.
    Butani L (2002) Corticosteroid-induced hypersensibility reactions. Ann Allergy Asthma Immunol 89:439–445PubMedGoogle Scholar
  21. 21.
    Latta K, von Schnakenburg C, Ehrich JH (2001) A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 16:271–282PubMedGoogle Scholar
  22. 22.
    Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, Ghio L, Lusvarghi E, Gusmano R, Locatelli F (1993) A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 43:1377–1384PubMedGoogle Scholar
  23. 23.
    Niaudet P (1994) Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr 125:981–986PubMedGoogle Scholar
  24. 24.
    Hymes LC (1995) Steroid-resistant, cyclosporine-responsive, relapsing nephrotic syndrome. Pediatr Nephrol 9:137–139PubMedGoogle Scholar
  25. 25.
    Sancewicz-Pach K, Slowiaczek E, Kwinta-Rybicka J, Wilkosz K, Drozdz D, Nowak J (1996) Long-term cyclosporine A (Sandimmun) therapy for steroid resistant nephrotic syndrome in children. Przegl Lek 53:365–368PubMedGoogle Scholar
  26. 26.
    Gregory MJ, Smoyer WE, Sedman A, Kershaw DB, Valentini RP, Johnson K, Bunchman TE (1996) Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis. J Am Soc Nephrol 7:543–549PubMedGoogle Scholar
  27. 27.
    Garcia C, Michelon T, Barros V, Mota D, Uhlmann A, Randon R, Ramalho H, Abbud FM (1998) Cyclosporine in the treatment of steroid-dependent and steroid-resistant idiopathic nephrotic syndrome in children. Transplant Proc 30:4156–4157PubMedGoogle Scholar
  28. 28.
    Habashy D, Hodson E, Craig J (2004) Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev CD003594Google Scholar
  29. 29.
    El-Husseini A, El-Basuony F, Mahmoud I, Sheashaa H, Sabry A, Hassan R, Taha N, Hassan N, Sayed-Ahmad N, Sobh M (2005) Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience. Nephrol Dial Transplant 20:2433–2438PubMedGoogle Scholar
  30. 30.
    Frassinetti Castelo Branco Camurca Fernandes P, Bezerra Da Silva G Jr, De Sousa Barros FA, Costa Oliveira CM, Kubrusly M, Evangelista JB Jr (2005) Treatment of steroid-resistant nephrotic syndrome with cyclosporine: study of 17 cases and a literature review. J Nephrol 18:711–720Google Scholar
  31. 31.
    Mahmoud I, Basuni F, Sabry A, El-Husseini A, Hassan N, Ahmad NS, Elbaz M, Moustafa F, Sobh M (2005) Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis. Nephrol Dial Transplant 20:735–742PubMedGoogle Scholar
  32. 32.
    McCauley J, Shapiro R, Ellis D, Igdal H, Tzakis A, Starzl TE (1993) Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 8:1286–1290PubMedPubMedCentralGoogle Scholar
  33. 33.
    McCauley J, Shapiro R, Scantlebury V, Gilboa N, Jordan M, Jensen C, Naik A, Tzakis A, Ellis D, Starzl TE (1991) FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. Transplant Proc 23:3354–3356PubMedPubMedCentralGoogle Scholar
  34. 34.
    Segarra A, Vila J, Pou L, Majo J, Arbos A, Quiles T, Piera LL (2002) Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 17:655–662PubMedGoogle Scholar
  35. 35.
    Loeffler K, Gowrishankar M, Yiu V (2004) Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol 19:281–287PubMedGoogle Scholar
  36. 36.
    Tsugawa K, Tanaka H, Nakahata T, Ito E (2004) Effective therapy of a child case of refractory nephrotic syndrome with tacrolimus. Tohoku J Exp Med 204:237–241PubMedGoogle Scholar
  37. 37.
    Cattran DC, Wang MM, Appel G, Matalon A, Briggs W (2004) Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 62:405–411PubMedGoogle Scholar
  38. 38.
    Bagga A, Hari P, Moudgil A, Jordan SC (2003) Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 42:1114–1120PubMedGoogle Scholar
  39. 39.
    Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB (2003) Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol 18:833–837PubMedGoogle Scholar
  40. 40.
    Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D (2002) Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 17:2011–2013PubMedGoogle Scholar
  41. 41.
    Chandra M, Susin M, Abitbol C (2000) Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil. Pediatr Nephrol 14:224–226PubMedGoogle Scholar
  42. 42.
    Mendizabal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J (2005) Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol 20:914–919PubMedGoogle Scholar
  43. 43.
    Fuchshuber A, Gribouval O, Ronner V, Kroiss S, Karle S, Brandis M, Hildebrandt F (2001) Clinical and genetic evaluation of familial steroid-responsive nephrotic syndrome in childhood. J Am Soc Nephrol 12:374–378PubMedGoogle Scholar
  44. 44.
    Karle SM, Uetz B, Ronner V, Glaeser L, Hildebrandt F, Fuchshuber A (2002) Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. J Am Soc Nephrol 13:388–393PubMedGoogle Scholar
  45. 45.
    Ruf RG, Lichtenberger A, Karle SM, Haas JP, Anacleto FE, Schultheiss M, Zalewski I, Imm A, Ruf EM, Mucha B, Bagga A, Neuhaus T, Fuchshuber A, Bakkaloglu A, Hildebrandt F (2004) Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 15:722–732PubMedGoogle Scholar

Copyright information

© IPNA 2007

Authors and Affiliations

  • Antonia Peña
    • 1
    Email author
  • Juan Bravo
    • 1
  • Marta Melgosa
    • 1
  • Carlota Fernandez
    • 1
  • Carmen Meseguer
    • 1
  • Laura Espinosa
    • 1
  • Angel Alonso
    • 1
  • M. Luz Picazo
    • 2
  • Mercedes Navarro
    • 1
  1. 1.NefrologíaHospital Infantil La PazMadridSpain
  2. 2.Department of PathologyHospital Universitario La PazMadridSpain

Personalised recommendations